A genomi mutációs mintázatok felhasználhatósága a daganatos betegségek diagnosztikájának és kezelésének javítására

Research concept

Personalised cancer therapy based on the molecular properties of tumours can increase survival while reducing side effects by the elimination of unnecessary therapies. Cancer is caused by genetic changes in somatic cells, and our work is aimed at utilising the genomic properties of tumour cells as biomarkers. To this end, we are modelling the genomic instability of tumour cells in genetically modified cultured cell lines, detectig mutation patterns using whole genome sequencing and a purpose-made bioinformatic pipeline. Our aim is to correlate identifiable mutational patterns to genetic defects and to treatment sensitivity.

Research services

1. CRISPR based gene knockout and gene modification in cell lines.
2. Determination of the mutagenicity of drugs, other compounds and environmental effects using whole genome sequencing of cultured cells.

Human resources

• Dávid Szüts, research group leader
• Dan Chen, research associate

Laboratories, rooms

Equipments

• Lonza 4D-Nucleofector System

Recent publications of the research group